Overexpression of S100A14 contributes to malignant progression and predicts poor prognosis of lung adenocarcinoma

Ding, Fang; Wang, Di; Li, Xukun; Yang, Lin; Liu, Huiying; Cui, Wei; Liu, Zhihua; Che, Yi-Qun

doi:10.1111/1759-7714.12654

Cited by 20 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First of all, there are several studies trying to identify how S100A14 is implicated in tumorigenesis by conducting experiments on cancer cell lines. However, it seems that S100A14 affects tumorigenic processes in a different way in different types of malignancies (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). In particular, S100A14 enhances proliferation and cell growth in breast (13), cervical (17), ovarian (18) and hepatocellular cancer (19), whereas it inhibits them in oral (23), esophageal (24) and urothelial cancer (27).…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, S100A14 facilitates cell migration in breast (14-16), cervical (17), ovarian (18), hepatocellular (19) and lung cancer (20,21), while it restrains it in gastric cancer (26). Similarly, under the influence of S100A14, motility is increased in breast cancer (15,16), but decreased in urothelial cancer (27), and invasiveness is increased in breast 16, cervical (17), ovarian (18), hepatocellular (19) and lung cancer (20,21), but decreased in oral (22) and gastric cancer (26). Finally, S100A14 seems to promote cell differentiation in esophageal (24) and gastric cancer (26), while it mediates epithelial-to-mesenchymal transition in cervical cancer (17).…”

Section: Discussionmentioning

confidence: 99%

“…Concerning the comparison between normal and malignant tissues, S100A14 expression is higher in malignant tissues in breast (13,19), ovarian (30), hepatocellular (19) and lung cancer (20), whereas it is lower in malignant tissues in colorectal cancer (34). As far as disease stage is concerned, high S100A14 levels are associated with advanced stages in cervical (17), ovarian (18), hepatocellular (19) and lung cancer (20,21), while they are associated with early stages in small bowel cancer (33). In addition, S100A14 expression is increased as the depth of infiltration is increased in lung cancer (20), whereas the exact opposite is true for gastric cancer (26).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, higher S100A14 levels are correlated to higher probability of lymph node metastasis in cervical (17) and lung cancer (20), but to lower probability of lymph node metastasis in gastric cancer (26). Similarly, increased production of S100A14 is associated with greater risk for distant metastases in lung cancer (21), but with reduced risk for distant metastases in gastric (26), small bowel (33) and colorectal cancer (34). In terms of tumor differentiation, S100A14 expression is higher in high-grade neoplasms in case of ovarian (18) and lung cancer (20,21) and in low-grade neoplasms in case of esophageal (24), gastric (26,32) and colorectal cancer (34).…”

Section: Discussionmentioning

confidence: 99%

“…Relapse-free survival rates of patients with higher (group 4) and lower (groups 1, 2, 3) S100A14 expression in colorectal cancer. (13-15, 28, 29), ovarian (18,31), hepatocellular (19) and lung cancer (20,21), but to longer survival in gastric (26,32) and colorectal cancer (34).…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

A Clinicopathological Analysis of S100A14 Expression in Colorectal Cancer

Diamantopoulou

Mantas

Kostakis

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: The calcium-binding protein S100A14 is involved in processes related to tumorigenesis and tumor propagation, such as proliferation, apoptosis, motility and invasiveness. Our aim was to investigate its role in colorectal cancer. Patients and Methods: One hundred and seven patients (65 men and 42 women) were included in this study. They had been diagnosed with colorectal cancer and undergone complete resection of their primary tumor. Tissue samples from archival blocks of their normal and malignant colorectal tissues were used for immunohistochemical assessment of S100A14 expression. S100A14 levels were evaluated using image analysis and associated with various clinicopathological parameters and prognosis. Results: S100A14 expression was reduced in malignant tissues when compared to normal intestinal mucosa in cases of T3-T4 tumors (p=0.017). Moreover, as far as S100A14 levels in malignant tissues are concerned, they were lower in T3-T4 tumors (p=0.001), N2 disease (p=0.034) and M1 disease (p=0.019). Finally, very high S100A14 production (>75 th percentile) was associated with shorter disease-specific (HR=3.584, p=0.045) and relapse-free survival (HR=4.527, p=0.007) in multivariate survival analysis. Conclusion: S100A14 expression is decreased in advanced colorectal cancer. However, cases with very high S100A14 levels have a worse survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A Clinicopathological Analysis of S100A14 Expression in Colorectal Cancer

Diamantopoulou

Mantas

Kostakis

et al. 2019

In Vivo

View full text Add to dashboard Cite

show abstract

STAT3‐mediated gene expression in colorectal cancer cells‐derived cancer stem‐like tumorspheres

Lin

Huang

et al. 2020

Adv in Digestive Medicine

View full text Add to dashboard Cite

STAT3 is a transcriptional factor involved in tumorigenesis and the initiation of cancer stemness property. However, the STAT3-downstream regulatory gene expressions in the formation of colorectal cancer (CRC)-derived tumorsphere is obscure.In this study, RNAseq was used to uncover the potential genes involved in the formation of colorectal HCT116-and HT29-derived stem-like tumorspheres, whereas HCT116 and HT29 overexpressed CD133. Furthermore, STAT3 was knockdowned and analyzed consequently by RNAseq for picking up the STAT3-mediated genes associated with tumorspheres formation. Then, quantitative polymerase chain reaction was used for validating the expressions of selected driver genes in epidermal growth factor (EGF) treated-and in STAT3-knockdowned HT29 cells. We found that 654 genes and 646 genes were upregulated in HCT116-and HT29-derived tumorspheres, respectively. There were 103 genes simultaneously increased in both CRC tumorspheres, including, STAT3 selected as a driver gene by NetworkAnalyst (https://www.networkanalyst.ca/). Moreover, there were 139 genes downregulated in HT29shSTAT3 cells compared to HT29shLuc cells, 12 of the genes were overlapped with the overexpressed 103 genes from tumorspheres, including, NDRG1,

show abstract

Proteomic analysis enables distinction of early‐ versus advanced‐stage lung adenocarcinomas

Kelemen

Plá

Sánchez

et al. 2020

Clinical & Translational Med

View full text Add to dashboard Cite

Background A gel‐free proteomic approach was utilized to perform in‐depth tissue protein profiling of lung adenocarcinoma (ADC) and normal lung tissues from early and advanced stages of the disease. The long‐term goal of this study is to generate a large‐scale, label‐free proteomics dataset from histologically well‐classified lung ADC that can be used to increase further our understanding of disease progression and aid in identifying novel biomarkers. Methods and results Cases of early‐stage (I‐II) and advanced‐stage (III‐IV) lung ADCs were selected and paired with normal lung tissues from 22 patients. The histologically and clinically stratified human primary lung ADCs were analyzed by liquid chromatography‐tandem mass spectrometry. From the analysis of ADC and normal specimens, 4863 protein groups were identified. To examine the protein expression profile of ADC, a peak area‐based quantitation method was used. In early‐ and advanced‐stage ADC, 365 and 366 proteins were differentially expressed, respectively, between normal and tumor tissues (adjusted P ‐value < .01, fold change ≥ 4). A total of 155 proteins were dysregulated between early‐ and advanced‐stage ADCs and 18 were suggested as early‐specific stage ADC. In silico functional analysis of the upregulated proteins in both tumor groups revealed that most of the enriched pathways are involved in mRNA metabolism. Furthermore, the most overrepresented pathways in the proteins that were unique to ADC are related to mRNA metabolic processes. Conclusions Further analysis of these data may provide an insight into the molecular pathways involved in disease etiology and may lead to the identification of biomarker candidates and potential targets for therapy. Our study provides potential diagnostic biomarkers for lung ADC and novel stage‐specific drug targets for rational intervention.

show abstract

Overexpression of S100A14 contributes to malignant progression and predicts poor prognosis of lung adenocarcinoma

Cited by 20 publications

References 19 publications

A Clinicopathological Analysis of S100A14 Expression in Colorectal Cancer

A Clinicopathological Analysis of S100A14 Expression in Colorectal Cancer

STAT3‐mediated gene expression in colorectal cancer cells‐derived cancer stem‐like tumorspheres

Proteomic analysis enables distinction of early‐ versus advanced‐stage lung adenocarcinomas

Contact Info

Product

Resources

About